HRT Financial’s Pacific Biosciences PACB Stock Holding History

HRT Financial’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,265,535	Closed	-$1.67M	–	5050
2026 Q1	$1.67M	Sell	1,265,535 -98,042	-7%	-$175K	﹤0.01%	1733
2025 Q4	$2.55M	Buy	+1,363,577	New	+$2.62M	0.01%	1142
2025 Q3	–	Sell	-106,280	Closed	-$131K	–	3452
2025 Q2	$131K	Sell	106,280 -37,563	-26%	-$43.4K	﹤0.01%	2159
2025 Q1	$169K	Buy	+143,843	New	+$221K	﹤0.01%	2059
2023 Q4	–	Sell	-134,188	Closed	-$1.12M	–	2880
2023 Q3	$1.12M	Buy	134,188 +109,475	+443%	+$1.25M	0.01%	904
2023 Q2	$328K	Buy	+24,713	New	+$300K	﹤0.01%	1574
2022 Q4	–	Sell	-151,070	Closed	-$876K	–	2962
2022 Q3	$876K	Buy	+151,070	New	+$867K	0.01%	1018
2022 Q2	–	Sell	-129,950	Closed	-$1.18M	–	3518
2022 Q1	$1.18M	Buy	+129,950	New	+$1.5M	0.01%	916
2021 Q4	–	Sell	-41,001	Closed	-$1.05M	–	3844
2021 Q3	$1.05M	Buy	+41,001	New	+$1.21M	0.01%	1225
2020 Q4	–	Sell	-240,493	Closed	-$2.37M	–	2295
2020 Q3	$2.37M	Buy	+240,493	New	+$1.38M	0.07%	197
2019 Q2	–	Sell	-24,477	Closed	-$176K	–	871
2019 Q1	$176K	Buy	+24,477	New	+$177K	0.03%	410

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

HRT Financial's PACB Position: Q2 2026 in Review

HRT Financial sold out of Pacific Biosciences (PACB) in Q2 2026, closing a stake of 1,265,535 shares — an estimated $1.67M sold.

HRT Financial first reported a position in PACB in Q1 2019 and held it in 11 quarters. The position peaked at $2.55M in Q4 2025. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

HRT Financial reported no remaining Pacific Biosciences position as of Q2 2026 after selling out during the quarter.
HRT Financial sold 1,265,535 Pacific Biosciences shares in Q2 2026, an estimated $1.67M.
HRT Financial first reported a position in Pacific Biosciences in Q1 2019 and held it in 11 quarters.
HRT Financial's Pacific Biosciences position peaked at $2.55M in Q4 2025.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.